{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-030583","form_type":"8-K","ticker":"TVRD","cik":"0001346830","company_name":"Tvardi Therapeutics, Inc.","filed_at":"2025-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.037445+00:00","generated_at":"2026-05-24T00:26:12.831126+00:00","sec_items":["5.07","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cara stockholders approve all six merger proposals with Tvardi; Tvardi posts $29.4M net loss","bullets":["All proposals passed: stock issuance for merger (2,088,293 for), equity plan, ESPP, reverse split (1:2-1:4), authorized shares increase to 150M, and advisory compensation.","Reverse stock split ratio between 1-for-2 and 1-for-4 to be mutually agreed by Cara and Tvardi boards before merger.","Tvardi audited 2024: net loss $29.4M (vs $17.3M in 2023), cash $31.6M, with going concern qualification.","Tvardi's lead candidate TTI-101 in Phase 2 for idiopathic pulmonary fibrosis and hepatocellular carcinoma.","Merger completion subject to customary closing conditions including Cara net cash of at least $18M at closing."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-030583","json":"https://secwatch.observer/filing/0001104659-25-030583.json","markdown":"https://secwatch.observer/filing/0001104659-25-030583.md","text":"https://secwatch.observer/filing/0001104659-25-030583.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1346830/000110465925030583/0001104659-25-030583-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1346830/000110465925030583/tm2510381d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T00:26:12.831126+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}